Key facts
- It has raised $64.0M; the latest was Early Stage VC ($54.0M) in Apr 2026.
- Notable investors include Qiming Venture Partners, Highlight Capital, Apricot Capital (Shanghai), TF Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Weicheng Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Weicheng Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Weicheng Pharmaceuticals
Developer of a proprietary extrahepatic drug delivery platform designed to advance targeted small nucleic acid therapies beyond hepatic tissues. The company offers specialized delivery mechanisms and preclinical pipeline innovations, enabling biotechnology developers focused on non-hepatic conditions to address critical therapeutic gaps with enhanced precision.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Weicheng Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Weicheng Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Weicheng Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.